MSCs may target monocytes, macrophages to reduce fibrosis

MSCs may target monocytes, macrophages to reduce fibrosis

Certain populations of immune monocytes and macrophages may be important targets of mesenchymal stem cell (MSC) therapy in idiopathic pulmonary fibrosis (IPF), according to a study. In an IPF mouse model, into-the-vein MSC treatment appeared to prevent monocytes from becoming a type of macrophage thought to promote the buildup…

Haduvio for IPF chronic cough wins new patent in US

Trevi Therapeutics has won approval of its patent application for Haduvio (nalbuphine extended-release tablets), an investigational treatment for chronic cough in people with idiopathic pulmonary fibrosis (IPF). The notice of allowance approving the application was issued on March 7 by the U.S. Patent and Trademark Office. The future…

How IPF can make it difficult to maintain a healthy weight

Achieving and maintaining a healthy weight, either through losing or sometimes gaining pounds, is an important part of our overall health and can often be accomplished through a nutritious diet and regular physical activity. However, weight maintenance becomes more complicated when you factor in a chronic illness. When I was…

Social workers play an integral role on my healthcare team

When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I became a patient at the Inova Fairfax Hospital’s Advanced Lung Disease and Transplant Center in Virginia. Inova is one of 81 locations included in the Pulmonary Fibrosis Foundation’s Care Center Network (CCN). One…